{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:43:48Z","timestamp":1785887028866,"version":"3.56.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014597","name":"LAM Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014597","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jaci.2026.02.034","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T16:28:21Z","timestamp":1772728101000},"page":"1127-1135.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Open-label phase 1b\/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema"],"prefix":"10.1016","volume":"157","author":[{"given":"Aleena","family":"Banerji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Craig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Sitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Henry","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Lumry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Adatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh S.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffi","family":"Tachdjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weily","family":"Soong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wedner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinisa","family":"Savic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ania","family":"Manson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Valerieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Gunsior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Mugundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"VanEenwyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kusumam","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M.","family":"Best","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2026.02.034_bib1","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1001\/archinte.163.10.1229","article-title":"Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency","volume":"163","author":"Bork","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaci.2026.02.034_bib2","doi-asserted-by":"crossref","first-page":"506","DOI":"10.2500\/aap.2009.30.3279","article-title":"Frequency, timing, and type of prodromal symptoms associated with hereditary angioedema attacks","volume":"30","author":"Prematta","year":"2009","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaci.2026.02.034_bib3","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1007\/s12325-022-02401-0","article-title":"Hereditary angioedema: diagnosis, clinical implications, and pathophysiology","volume":"40","author":"Sinnathamby","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaci.2026.02.034_bib4","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMcp0803977","article-title":"Clinical practice. Hereditary angioedema","volume":"359","author":"Zuraw","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.02.034_bib5","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/archinte.161.20.2417","article-title":"Hereditary angioedema: a broad review for clinicians","volume":"161","author":"Nzeako","year":"2001","journal-title":"Arch Intern Med"},{"issue":"14 suppl","key":"10.1016\/j.jaci.2026.02.034_bib6","first-page":"S299","article-title":"Current and emerging therapies to prevent hereditary angioedema attacks","volume":"24","author":"Lumry","year":"2018","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jaci.2026.02.034_bib7","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jaip.2021.11.011","article-title":"Specific targeting of plasma kallikrein for treatment of hereditary angioedema: a revolutionary decade","volume":"10","author":"Busse","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.02.034_bib8","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/all.12380","article-title":"Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group","volume":"69","author":"Cicardi","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.02.034_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2023.100758","article-title":"A narrative review of recent literature of the quality of life in hereditary angioedema patients","volume":"16","author":"Chong-Neto","year":"2023","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaci.2026.02.034_bib10","series-title":"Cinryze (C1 esterase inhibitor [human]) for intravenous use, freeze-dried powder for reconstitution","year":"2022"},{"key":"10.1016\/j.jaci.2026.02.034_bib11","series-title":"Haegarda (C1 esterase inhibitor subcutaneous [human]) for subcutaneous injection, freeze-dried powder for reconstitution","year":"2020"},{"key":"10.1016\/j.jaci.2026.02.034_bib12","series-title":"Takhzyro (lanadelumab-flyo) injection, for subcutaneous use","year":"2022"},{"key":"10.1016\/j.jaci.2026.02.034_bib13","series-title":"Orladeyo (berotralstat) capsules, for oral use","year":"2025"},{"key":"10.1016\/j.jaci.2026.02.034_bib14","series-title":"Andembry (garadacimab-gxii) injection, for subcutaneous use","year":"2025"},{"key":"10.1016\/j.jaci.2026.02.034_bib15","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJM197612232952602","article-title":"Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities","volume":"295","author":"Gelfand","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2026.02.034_bib16","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema\u2014the 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.02.034_bib17","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1742-7843.2006.pto_271.x","article-title":"Pain perception after subcutaneous injections of media containing different buffers","volume":"98","author":"Laursen","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.jaci.2026.02.034_bib18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.anai.2025.03.016","article-title":"Safety and pharmacokinetics of long-acting plasma kallikrein inhibitor navenibart (STAR-0215) in healthy adults","volume":"135","author":"Lumry","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2026.02.034_bib19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.anai.2010.01.007","article-title":"The bradykinin-forming cascade and its role in hereditary angioedema","volume":"104","author":"Kaplan","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2026.02.034_bib20","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1124\/jpet.123.001740","article-title":"STAR-0215 is a novel, long-acting monoclonal antibody inhibitor of plasma kallikrein for the potential treatment of hereditary angioedema","volume":"387","author":"Bedian","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaci.2026.02.034_bib21","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1182\/blood.V77.12.2660.2660","article-title":"Alpha 2-macroglobulin\u2013kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis","volume":"77","author":"Kaufman","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2026.02.034_bib22","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/cts.12806","article-title":"Pharmacokinetics, pharmacodynamics, and exposure-response of lanadelumab for hereditary angioedema","volume":"13","author":"Wang","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jaci.2026.02.034_bib23","unstructured":"Chung JK, Luo H, Tolsma J, Bista, Nichols A, Morabito C. Mechanistic modeling and simulations predict long-term HAE attack prevention with STAR-0215. Paper presented at: 13th C1-Inhibitor Deficiency and Angioedema Workshop; May 4-7, 2023; Budapest, Hungary. Abstract HU2023."},{"key":"10.1016\/j.jaci.2026.02.034_bib24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s41687-025-00876-3","article-title":"Content validation of the Angioedema Quality of Life Questionnaire (AE-QoL) in a population of adult and adolescent patients with hereditary angioedema (HAE)","volume":"9","author":"Broderick","year":"2025","journal-title":"J Patient Rep Outcomes"},{"key":"10.1016\/j.jaci.2026.02.034_bib25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/PPA.S70834","article-title":"Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective","volume":"9","author":"Bolge","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jaci.2026.02.034_bib26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2147\/PPA.S187120","article-title":"Mode of injection and treatment adherence: results of a survey characterizing the perspectives of health care providers and US women 18-45 years old","volume":"13","author":"Gandell","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jaci.2026.02.034_bib27","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/all.12900","article-title":"The Angioedema Quality of Life Questionnaire (AE-QoL)\u2014assessment of sensitivity to change and minimal clinically important difference","volume":"71","author":"Weller","year":"2016","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2026.02.034_bib28","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/AAC.01285-13","article-title":"A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults","volume":"57","author":"Robbie","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jaci.2026.02.034_bib29","article-title":"Impact of half-life extension via YTE modification on the duration of action, efficacy, and safety of monoclonal antibodies: a systematic literature review","volume":"209","author":"Whelan","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2026.02.034_bib30","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/cid\/ciae596","article-title":"Lower respiratory tract infections following respiratory syncytial virus monoclonal antibody nirsevimab immunization versus placebo: analysis from a phase 3 randomized clinical trial (MELODY)","volume":"81","author":"Arbetter","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaci.2026.02.034_bib31","series-title":"Exdensur (depemokimab-ulaa) injection, for subcutaneous use","year":"2025"},{"key":"10.1016\/j.jaci.2026.02.034_bib32","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1007\/s12325-025-03457-4","article-title":"Safety and tolerability of twice-yearly depemokimab in patients with asthma and chronic rhinosinusitis with nasal polyps: pooled results from SWIFT-1\/-2 and ANCHOR-1\/-2","volume":"43","author":"Jackson","year":"2026","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaci.2026.02.034_bib33","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.1016\/j.jaip.2021.08.019","article-title":"Racial and ethnic disparities in the research and care of hereditary angioedema patients in the United States","volume":"9","author":"Sylvestre","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2026.02.034_bib34","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1016\/j.jaip.2022.08.016","article-title":"Racial and ethnic disparities in biologic prescriptions for asthma in the United States","volume":"10","author":"Sylvestre","year":"2022","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926001715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674926001715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:40:07Z","timestamp":1781685607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674926001715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0091674926001715"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2026.02.034","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Open-label phase 1b\/2 trial of navenibart, a long-acting plasma kallikrein inhibitor for hereditary angioedema","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2026.02.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}